Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetesDIABETES OBESITY & METABOLISMIF5.72018-12-18138PREAI
Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover studyDIABETES OBESITY & METABOLISMIF5.72015-01-0575OAAI
PHARMACODYNAMIC (PD) DIFFERENCES BETWEEN CANAGLIFLOZIN (CANA) 300 MG AND DAPAGLIFLOZIN (DAPA) 10 MG FOR URINARY GLUCOSE EXCRETION (UGE), RENAL THRESHOLD FOR GLUCOSE (RTG), AND POSTPRANDIAL PLASMA GLUCOSE (PPG) EXCURSION IN HEALTHY PARTICIPANTSDIABETES RESEARCH AND CLINICAL PRACTICEIF7.42014-11-010PREAI
Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitusDIABETES OBESITY & METABOLISMIF5.72014-07-08208PREAI
Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion Results of a randomized, placebo-controlled studyDIABETES CAREIF16.62013-07-11219OAAI